Dopamine modulates the neural representation of subjective value of food in hungry subjects 1 Title: Dopamine modulates the neural representation of subjective value of food in hungry subjects 2 3 4 Abbreviated title: Dopamine modulates the neural representation of value 5 Authors: 6 Medic, Nenad 7 8 ¹ Dept. of Psychiatry, University of Cambridge, Cambridge CB2 0SZ, UK 9 ² Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge 10 CB2 0QQ, UK 11 nm483@cam.ac.uk 12 Ziauddeen, Hisham 13 14 ¹ Dept. of Psychiatry, University of Cambridge, Cambridge, CB2 0SZ, UK ² Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge 15 16 CB2 0QQ, UK 17 ³ Cambridgeshire & Peterborough NHS Foundation Trust, Cambridge CB21 5EF, UK 18 hz238@cam.ac.uk 19 20 Vestergaard, Martin D ⁴ Dept. of Physiology, Development and Neuroscience, University of Cambridge, Cambridge 21 CB2 3DY, UK 22 23 mdv23@cam.ac.uk 24 25 Henning, Elana 26 ² Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge CB2 0QQ, UK 27

- 28 <u>eh330@medschl.cam.ac.uk</u>
- 29
- 30 Schultz, Wolfram
- 31 ⁴ Dept. of Physiology, Development and Neuroscience, University of Cambridge, Cambridge
- 32 CB2 3DY, UK
- 33 <u>ws234@cam.ac.uk</u>
- 34
- 35 Farooqi, I Sadaf
- ² Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge
- 37 CB2 0QQ, UK
- 38 <u>isf20@cam.ac.uk</u>
- 39
- 40 Fletcher, Paul C
- 41 ¹ Dept. of Psychiatry, University of Cambridge, Cambridge CB2 0SZ, UK
- 42 ² Wellcome Trust-MRC Institute of Metabolic Science, University of Cambridge, Cambridge
- 43 CB2 0QQ, UK
- 44 ³ Cambridgeshire & Peterborough NHS Foundation Trust, Cambridge CB21 5EF, UK
- 45 <u>pcf22@cam.ac.uk</u>
- 46

47 **Corresponding author:**

- 48 Medic, Nenad
- 49 Wellcome Trust-MRC Institute of Metabolic Science
- 50 Level 4, Addenbrooke's Hospital, University of Cambridge
- 51 Box 289, CB2 0QQ, Cambridge, UK
- 52 +44-1223-761219
- 53 <u>nm483@cam.ac.uk</u>
- 54

- 55 **Number of pages:** 40
- 56 **Number of figures:** 5
- 57 Number of tables: 4
- 58 Number of words:
- **a) Abstract:** 141 words
- 60 **b)** Introduction: 475 words
- **c) Discussion:** 1479 words
- 62 **d)** Total: 8007 words

63 **Conflict of interest:**

64 The authors declare no conflict of interest.

65 Acknowledgements:

- 66 We thank all the participants and the staff of the Wolfson Brain Imaging Centre. This study was
- 67 supported by the NIHR/Wellcome Trust Clinical Research Facility, Bernard Wolfe Health
- 68 Neuroscience Fund (HZ, EH, ISF, PCF), the Wellcome Trust (NM, HZ, MDV, EH, WS, ISF, PCF), the
- 69 NIHR Cambridge Biomedical Research Centre (EH, ISF), the European Research Council (MDV,
- 70 WS) and the National Institutes of Health Caltech Conte Center (MDV, WS).
- 71
- 72
- 73
- 74
- 75
- 76
- 77
- 78
- 79
- 80
- 81

82 <u>Abstract</u>

83 While there is a rich literature on the role of dopamine in value learning, much less is known about its role in using established value estimations to shape decision-making. Here we 84 investigated the effect of dopaminergic modulation on value-based decision-making for food 85 86 items in fasted healthy human participants. The Becker-deGroot-Marschak auction, which 87 assesses subjective value, was examined in conjunction with pharmacological functional magnetic resonance imaging (fMRI) using a dopaminergic agonist and an antagonist. We found 88 that dopamine enhanced the neural response to value in the inferior parietal 89 gyrus/intraparietal sulcus, and that this effect predominated towards the end of the valuation 90 91 process when an action was needed to record the value. Our results suggest that dopamine is involved in acting upon the decision, providing additional insight to the mechanisms underlying 92 impaired decision-making in healthy individuals and clinical populations with reduced 93 94 dopamine levels.

96 Introduction

Successful interactions with the environment - those that maximise reward and minimise 97 punishment – entail using previous experience to predict the likely value of outcomes and the 98 99 actions that obtain them. Animal and human studies have strongly implicated the 100 neurotransmitter dopamine in this value learning process (Bayer and Glimcher, 2005; Schultz, 101 1998; Schultz et al., 1997; Steinberg et al., 2013; Wise, 2004; Frank and O'Reilly, 2006; Frank et 102 al., 2004; Pessiglione et al., 2006), in addition to its other overlapping roles in shaping behaviour, including motivation (Berridge and Robinson, 1998), vigour (Niv et al., 2007) and 103 104 behavioural activation (Robbins and Everitt, 2007).

105 But choice requires not merely an ability to predict the consequences of one's actions. One must 106 be able to weigh up the likely values of competing possibilities. Thus, it is critical to retrieve and 107 represent the subjective values of the options on offer in order to select the most valuable one. 108 This value computation – an intrinsic part of decision-making - has been linked to the function 109 of certain key brain regions in humans and non-human primates, including the ventromedial prefrontal cortex (vmPFC), ventral striatum, posterior parietal and supplementary motor cortex 110 111 (Bartra et al., 2013; Clithero and Rangel, 2013; Hunt et al., 2012; O'Doherty, 2011; Platt and 112 Glimcher, 1999; Wunderlich et al., 2009). The key question posed in the current study is whether value-related processes in these regions may be modulated by dopamine. 113

114 Single cell recordings from dopamine neurons responding to reward-predicting stimuli have implicated dopamine in the neural coding of the subjective value of stimuli (Fiorillo et al., 2003; 115 Roesch et al., 2007; Tobler et al., 2005). Furthermore, recent pharmacological studies suggested 116 a role of dopamine in the optimal selection of most valuable stimuli within probabilistic learning 117 tasks (Jocham et al., 2011; Shiner et al., 2012; Smittenaar et al., 2012). However, there is a 118 critical distinction between value updating (learning) and value-based decision-making, and 119 120 these cannot be fully dissociated within probabilistic learning tasks. Whereas both processes 121 are hypothesised to be modulated by dopamine (McClure et al., 2003), the distinct role of

dopamine in decision-making, dissociated from learning, has not been experimentally
investigated. To address this, we conducted a between-subject, placebo-controlled
pharmacological fMRI study in healthy volunteers.

We explored the effects of both a dopamine agonist and an antagonist on the subjective 125 126 valuation of food items in a Becker-deGroot-Marschak (BDM) mechanism (Becker et al., 1964). The BDM replicates many aspects of second-price auctions and provides a robust means of 127 128 obtaining subjective values and involves no learning component. It has been used in human neuroscience before (Grether et al., 2007; Plassmann et al., 2007). All items in the auction were 129 well-known everyday foods whose value subjects would have acquired through life experience, 130 independent of our experimental manipulation. This enabled us to characterise the impact of 131 dopaminergic modulation on the behavioural and brain processes associated primarily with 132 decision-making. 133

135 Materials and methods

136 Subjects

Forty-seven healthy, right-handed people (23 males, aged 23.8±3.2, body mass index 21.7±1.6
kg/m² (mean±SD)) participated in the study. All subjects had normal or corrected to normal
vision, had no history of psychiatric or other significant medical history, and reported no
contraindications to the pharmacological agents or MRI scanning.

The study was approved by the Cambridge East Local Research Ethics Committee (REC 142 11/EE/0480) and was conducted at the Wellcome Trust Clinical Research Facility and the 143 Wolfson Brain Imaging Centre in Addenbrooke's Hospital, Cambridge, UK. The study was 144 carried out in accordance with the principles of the Declaration of Helsinki. All participants 145 provided written, informed consent.

146 Study design

In a double-blind, between-subject study, subjects received a single oral dose of either 147 148 bromocriptine 1.25 mg (dopamine D2 agonist, n=15), sulpiride 400 mg (D2 antagonist, n=16) or placebo (n=16). One subject (from the sulpiride group) did not pay attention to the task and was 149 excluded from the analysis (on over 50% of the free trials, the subject placed a bid of £0; when 150 debriefed, she did not express any dislike of the food items on offer or a desire to keep her 151 budget, thus calling into question her understanding of the task). Three additional subjects (one 152 from each group) were excluded from the fMRI analysis because of severe signal dropout in the 153 154 frontal lobe, as agreed on visual inspection by the study analysis team. This left 46 datasets (23 males, aged 23.8±3.2, body mass index 21.7±1.6 kg/m² (mean±SD)) for the behavioural analysis 155 156 and 43 datasets (21 males, aged 23.6 \pm 2.9, body mass index 21.5 \pm 1.5 kg/m² (mean \pm SD)) for the fMRI analysis. Subjects' age (F = 0.45, p = 0.64), BMI (F = 1.02, p = 0.37) or gender (χ^2 = 0.04, p = 157 0.98) did not differ between the treatment groups. In addition to the task described below, 158 participants underwent a number of other cognitive measures, which are not presented here. 159

Subjects attended the study session in the morning following an overnight fast. They received a standardised breakfast (based on body weight, age and gender) on the clinical research facility at 8am. This was to ensure similar baseline metabolic states across subjects and to minimise pharmacokinetic perturbations related to food and drink.

164 Bromocriptine and sulpiride have been used in previous studies (Cools et al., 2009; Dodds et al., 165 2009; Morcom et al., 2010), and are well tolerated at these doses. As bromocriptine can cause 166 nausea (Bromocriptine SPC, 2012), to maintain the double-blinding and prevent any effects of nausea on performance on a food-related task, all subjects were prophylactically given 10 mg of 167 168 the anti-emetic domperidone, which does not cross the blood-brain barrier (Domperidone SPC, 2012). Bromocriptine reaches peak plasma levels 1-3 hours post dose, with a half-life of about 169 15 hours (Kvernmo et al., 2006). Sulpiride reaches its maximal plasma concentration about 3 170 hours post dose, and has a plasma half-life of about 12 hours (Caley and Weber, 1995; Wiesel et 171 172 al., 1980). The study drug and domperidone were given to all participants at 11am. The fMRI 173 acquisition started approximately 2.5 hours after receiving the drugs (at \sim 1:30 pm) to capture 174 the window of maximal drug effect.

175 fMRI task

A computerised version of the BDM auction was developed, in which participants could bid for
50 different foods, represented by photographs (see Figure 1A). Participants were given a fixed
budget, and the auction procedure incentives participants to place bids as close as possible to
their real subjective value.

In addition to their study participation fee, before entering the scanner, participants were handed a budget of £3 for bidding. This was physically given to them to ensure they regarded the budget as their own money. They were instructed that on each trial they could place a bid between £0 and £3 for the presented item. Responses were made on a sliding scale that went from £0 to £3 in increments of 20 pence. Participants were told that the computer would bid against them on each trial but the bid would not be disclosed to them. As per the rules of the

186 auction, one trial would be randomly selected at the end of the auction (subjects therefore did not have to spread their £3 budget across different trials, and were instructed to treat every 187 trial as if it were the only one). If their bid for the food item on the selected trial was larger than 188 the computer's, they would win that food item, get a chance to eat it after the scanning session 189 190 and only have to pay the amount the computer bid (which would be less than their bid) and keep any remaining change. If, however, the computer outbid them or matched their bid, they 191 would not win the food item but would get to keep their £3 budget. Given this set-up, the 192 193 auction is incentive-compatible, i.e. the best strategy is to place a bid close to what one is 194 actually willing to pay. As the actual amount paid is determined by the computer's bid on the 195 selected trial, bidding higher amounts risks having to pay more than one's subjective value. Bidding lower amounts runs the risk of losing the opportunity to win the item (more cheaply 196 197 than one was prepared to pay for it). These rules were all explicitly stated and emphasised to the subjects as part of the task instructions. Critically, participants were in a hungry state and 198 were told that they could eat any food they won after the scanning session. 199

Since each trial entails a number of perceptuomotor components, we used an approach taken by Plassmann et al., (2007), by including a control task in which the same 50 foods were presented in "forced" trials (as opposed to the above "free" trials) where subjects were instructed to bid an amount taken from a random distribution of possible bids from £0 to £3 pounds, again in 20 pence increments. These trials required participants to engage in all the processes involved in the free trials with the critical difference of requiring no subjective valuation. Moreover, participants were aware that they would not lose money on such trials.

Fifty trials of each trial type (free and forced), of duration 8 seconds, were presented in a randomised order. The picture of the food was presented throughout the entire 8-second duration of a trial. The initial position of the cursor on the sliding scale varied randomly. Participants placed bids using a standard button box with the first and second buttons serving to move the cursor down or up the sliding value scale in steps of 20 pence, and the third button

- serving to confirm the final bid and mark the end of the bidding. From this point until the end of
 the 8-second bidding trial, the cursor could not be moved further. When the 8-second bidding
 trial was over, a feedback screen showing the final bid was presented (Figure 1A). If the bid was
 not confirmed within 8 seconds, the feedback screen stated "Not quick enough". In the analysis,
 these trials were considered missed trials.
- In fact, for practical reasons, the task was set up to ensure that subjects did not win a food item,but instead ended up keeping their £3 budget.

219 Behavioural analysis

- 220 Behavioural data were analysed using mixed-effects models (nlme package in R (Pinheiro et al.,
- 221 2013)), with subjects as a random effect. Post-hoc comparisons, where needed, were done using
- the multcomp package (Hothorn et al., 2008).

223 fMRI data acquisition and analysis

224 All data were acquired on a Siemens Verio scanner operating at 3 Tesla with a 192mm field of view at the Wolfson Brain Imaging Centre, Cambridge, UK. A total of 570 gradient echo T2*-225 weighted echo planar images (EPI) depicting blood oxygenation level dependent (BOLD) 226 contrast were acquired for each participant. The first six images were discarded to avoid T1 227 equilibration effects. Images comprised 31 slices, each 3mm thick with a 0.8mm inter-slice gap 228 229 and a 64 × 64 data matrix. Slices were acquired in an ascending interleaved fashion, repetition time = 2000ms, echo time = 30ms, flip angle = 78°, axial orientation = oblique. Data were 230 231 analysed using statistical parametric mapping in the SPM8 program (www.fil.ion.ucl.ac.uk). Images were realigned then spatially normalised to a standard template and spatially smoothed 232 233 with an isotropic 3 dimensional Gaussian filter (8 mm full width at half maximum). The time 234 series in each session were high-pass filtered (with cut-off frequency 1/120 Hz) and serial autocorrelations were estimated using an AR(1) model. 235

237 Model 1: Brain responses to value across the entire bidding period and its modulation by 238 dopamine

Each bidding trial was modelled as a boxcar function, from the onset of the food stimulus until the bid was confirmed (duration equal to RT, Figure 1B). Separate regressors were created for free and forced trials. Free and forced bids were used as parametric modulators of these regressors. Missed trials (in which no bids were selected within 8 seconds) were modelled as a separate regressor. All regressors were convolved with a canonical haemodynamic response function with a temporal derivative. Six motion realignment parameters were included as regressors of no interest.

To examine processes specifically associated with valuation, we calculated the first-level 246 247 contrasts as the difference between the parametric modulator of free bid in free trials and 248 forced bid in forced trials. Given that in forced trials subjects implemented instructed bids, these 249 trials should not engage the circuitry of interest to us but they should engage all other nonspecific processes related to valuation. The applied contrast thus corrects for non-specific 250 effects and enables identification of regions specifically involved in the valuation-based decision 251 process. Single-subject contrast images were then entered into a second-level group analysis, 252 with subjects as a random effect. 253

254 At the second level, two analyses were performed:

1. To explore which brain regions are involved in valuation across all subjects, independent of pharmacological treatment, we computed a one-sample t-test on the single-subject contrast coefficients from all 43 participants. The analysis was conducted within a pre-defined 10mm radius sphere in the vmPFC (from the work of Chib et al. (2009)), with a family-wise error (FWE) small-volume corrected threshold of p<0.05. This was based on our a priori hypothesis given the strong evidence implicating this region in value computation. In addition, we explored the existence of value related signals across the whole brain, adopting a threshold of p<0.05,</p>

262 FWE corrected at the cluster-level. Additionally, for completeness, we explored the existence of brain regions whose neural activity separately correlated with free bids in free trials and forced 263 bids in forced trials. We also explored whether there was a region whose activity tracked the 264 mismatch between free bid and the randomly ascribed forced bid for the same food item during 265 forced trials; this entailed examining the existence of correlation between neural activity during 266 forced trials and a parametric modulator of the difference between the free bid and the randomly 267 ascribed forced bid for same food item. These additional analyses were conducted at the whole-268 269 brain level, using a more liberal threshold of p<0.001, uncorrected.

270 2. To explore the effect of the dopaminergic modulation on the neural representation of value, 271 we performed a non-directional F-test (ANOVA). This was again conducted within the vmPFC ROI, applying a small-volume corrected threshold of p<0.05, and at the whole-brain level, at a 272 more liberal threshold of p<0.001 uncorrected, k>20 voxels. This threshold at the whole-brain 273 level was adopted because it is not possible to apply a cluster-level correction for F-tests in 274 SPM8 and a voxel-level correction would be too stringent. In case of significant effects, they 275 were further delineated using two-sample t-tests at the whole-brain cluster-level and within the 276 vmPFC sphere, at a FWE corrected threshold of p<0.05. 277

278

279 *Model 2: Does dopamine have different contributions to different phases of the* 280 *bidding/valuation process?*

This post-hoc analysis aimed to establish the temporal specificity of the dopaminergic effects and, in so doing, to relate them to the early (initial valuation) and late (value-dependent action) stages of the bidding process. A modified first-level model was estimated that looked for changes in the correlation of BOLD activity with the bid separately for early and late phases of each trial.

286

287 To model the early and late stages of the bidding process, two regressors were created for each

288 subject. These two regressors were modelled as 0s stick functions: an early period regressor was set at the time of food photo (and trial) onset, and a late period regressor was set at a time 289 half-way from the food photo onset to the bid confirmation (RT/2). This was done separately 290 for each trial (Figure 1C). Whereas at the first time point no responding took place, at the 291 second time point, participants were responding to select the bid. Missed early and late 292 regressors were modelled as separate 0s stick functions, with the late time point regressor 293 294 modelled at 4s (halfway through the trial). The parametric modulators of bids for early and late 295 time points were the same for a given trial. To identify neural representations of value at each 296 time point, two separate single-subject contrasts were computed: the early neural 297 representation of value as the difference between the parametric modulator of free bid and forced bid at the early time point; and the late neural representation as the difference between 298 the parametric modulator of free bid and forced bid at the late time point. 299

300

The two contrast images per each individual were put forward to the second-level group analysis, with subjects as a random effect. At the group level we used a 2x3 factorial ANOVA to explore the interaction between time and drug on the neural representation of value. This analysis was confined to a 10mm-radius sphere around the peak voxel exhibiting the strongest dopaminergic modulation of neural representation of value, established in the previous analysis. The analysis was conducted at a FWE small-volume corrected threshold of p<0.05.

308 <u>Results</u>

309 Behavioural results

310 *Missed trials*

311 Predictably, there were significantly fewer missed trials within the free than in the forced trials

312 (free (mean±SEM): 0.48± 0.12, forced (mean±SEM): 1.52± 0.27, F=17.49, p=0.0001), however

this did not differ across groups (trial type-by-group interaction F=0.14, p=0.87).

314 Bid

Despite a clear trend for higher free bids in the sulpiride group (Figure 2A), the effect of treatment did not reach significance (F=2.83, p=0.07). Pairwise comparisons revealed a strongest difference between sulpiride and bromocriptine, however this did not reach significance (sulpiride versus bromocriptine, z=2.16; p=0.08, placebo versus bromocriptine z=0.23, p=0.97; sulpiride versus placebo z=1.96, p=0.12, Tukey-corrected for multiple comparisons).

Free bids were found to be positively correlated with the initial random position of cursor on the bidding scale (t=6.09, p<0.0001), however, this did not differ between different treatment groups (initial cursor position-by-treatment group interaction F=1.76, p=0.17). Adding the initial cursor position as the covariate into the model exploring the effect of treatment group on the bid did not change the reported results.

326 Reaction time

Individual reaction times (RTs) were, of course, dependent on the initial position of the cursor since this would determine how far they were required to move in order to finalise the selection. There was thus a correlation between starting point and RT (t=10.15, p<0.0001). To account for this, the number of button presses made to select the bid was entered as a covariate into the model exploring the effect of trial type and drug treatment on RT. The analysis revealed

332 a significant effect of trial type (F=398.39, p<0.0001), with subjects, as expected, being quicker on forced compared to free trials (Figure 2B). There was no main effect of treatment (F=1.01, 333 p=0.37), however there was a significant treatment-by-trial type interaction (F=3.7, p=0.025). 334 None of the pairwise comparisons between drug treatments in the free condition reached 335 significance, however, as evident from the plot, there was a trend of shorter RTs under sulpiride 336 in comparison to placebo and bromocriptine (placebo versus bromocriptine z=0.47, p=0.86; 337 sulpiride versus bromocriptine z=-1.29, p=0.39; sulpiride versus placebo z=-1.78, p=0.18; 338 339 Tukey corrected for multiple comparisons). As evident from the plot, the analogous analysis 340 within the forced trials revealed no difference in reaction RTs between drug treatments 341 (placebo versus bromocriptine z=-0.46, p=0.89; sulpiride versus bromocriptine z=-0.85, p=0.67; sulpiride versus placebo z=-0.41, p=0.91; Tukey corrected for multiple comparisons). 342

343 fMRI results

As described above, two key analyses were performed. Our first analysis treated the entire 344 duration of the bidding (equal to RT, mean $RT\pm SD = 4.1\pm 1.37s$) as the period of interest to 345 identify regions sensitive to value and dopaminergic modulation (Model 1, Figure 1B). Next we 346 347 sought to determine whether in these regions, there were differential effects of dopamine on different aspects of the bidding process (Model 2, Figure 1C). Model 2 examined whether the 348 drug effects were specific to a particular stage of each trial. Dividing every trial into early and 349 late phases (corresponding approximately to initial valuation and value-dependent action) on 350 351 the basis of the response made, we explored the interaction between drug, value (bid size) and 352 trial phase (early versus late).

353

354

355

357 The neural representation of value (Model 1)

358 Examination of the brain regions involved in valuation across all study participants revealed 359 activity correlating with subjective value within the pre-defined region of vmPFC (p_{FWE} <0.05, small volume corrected, Figure 3A), consistent with theory and previous work (Bartra et al., 360 2013; Clithero and Rangel, 2013). Further, several clusters were seen (whole-brain cluster-level 361 p_{FWE}<0.05) including a large cluster encompassing the left and right posterior parietal cortex 362 (maxima located in the region of intraparietal sulcus (IPS) on both sides) and extending to the 363 left fusiform gyrus and further clusters in middle and inferior frontal gyri bilaterally and in the 364 right fusiform/lingual gyrus (Figure 3B and Table 1). 365

366 For completeness, we conducted two additional analyses. Firstly, we explored the correlation of neural activity with free and forced bids separately. Whereas the neural activity correlating with 367 free bids in free trials mimicked the pattern of neural activity in our main contrast, there was no 368 region, even at a liberal threshold of p<0.001 uncorrected, whose activity correlated with forced 369 bids in forced trials. This confirms that the effects established in our main contrast were not 370 driven by activity associated with forced trials. Secondly, we also investigated whether there 371 372 was a region whose activity tracked the mismatch between free bid and the randomly ascribed 373 forced bid for the same food item during forced trials. That is, we determined whether being 374 forced to make a bid that markedly deviated from how one would normally value a given item was associated with enhanced responses. However, no such region was detected, even at a 375 liberal threshold of p<0.001 uncorrected. 376

377 Dopaminergic drugs modulate the neural response to value in the left and right inferior 378 parietal gyrus/intraparietal sulcus (Model 1)

We next explored the effect of the administered dopaminergic drugs on the valuationdependent brain activity. The ANOVA comprising the three levels of pharmacological treatment found no effect of treatment in the vmPFC (this was also true for a more liberal threshold,

p<0.001 uncorrected). A significant effect of dopaminergic treatment was found in the right
middle frontal gyrus and in the left and right inferior parietal gyrus, in close vicinity of the IPS
(IPG/IPS; p<0.001 uncorrected, k>20 voxels; Table 2, Figure 4A).

To establish more precisely what drove this effect, additional two-sample t-tests were performed. Compared to sulpiride, bromocriptine was associated with a stronger relationship between value and activity in the IPG/IPS bilaterally (corrected for multiple comparisons at the cluster-level, p_{FWE}<0.05, Table 3, Figures 4B and 4D); in other words, it increased the strength of correlation between the bids and the BOLD response. Further t-tests between individual pharmacological treatments did not reveal any significant clusters at the same threshold.

Interestingly, these two clusters were close to the posterior parietal cluster identified in the previous contrast. As can be seen from the parameter estimates (Figure 4C), there was a trend towards reduced neural representation of value within the sulpiride group in the posterior parietal cluster, however, the clear distinction between the groups was only seen in the L- and R-IPG/IPS clusters.

In summary, we found that the neural response to value is significantly affected by pharmacological manipulation of dopaminergic function in the IPG/IPS region and this effect was driven by the bromocriptine versus sulpiride contrast.

399 Dopaminergic treatment modulates the neural representation of value in the left inferior 400 parietal gyrus/intraparietal sulcus during the late stage of valuation (Model 2)

Here, we investigated whether the dopaminergic modulation is specific to the early or late stage of the valuation process. We focused specifically on the regions showing an effect of drug across the whole trial, splitting this trial into early and late phases (with the split-point determined based on time-to-decision for each trial separately). A significant time-by-drug interaction was established in a 10mm-radius sphere around the peak voxel in the left IPG/IPS demonstrating the strongest effect of dopaminergic treatment in the previous model (p_{FWE}<0.05, small volume

corrected, Table 4, Figure 5A). As evident from the parameter estimates extracted from each of 407 six conditions (Figure 5B), the effect of dopaminergic manipulation on valuation was greater 408 during the later (value-dependent action) phase compared to the earlier (initial valuation) 409 phase. This result suggests that the modulation of strength of correlation between the bids and 410 the BOLD signal in the left IPG/IPS, increasing with bromocriptine and decreasing with 411 sulpiride, becomes more pronounced closer to the point when an appropriate action is used to 412 record the final bid, i.e. when the participant makes a fine-grained decision about whether the 413 414 bid should be 20p more or less, which in the context of our task might indicate a dopaminergic 415 influence on the fine tuning of the valuation process.

417 Discussion

In this pharmacological fMRI study we used the established BDM mechanism with food rewards, in a sample of hungry participants, to assess the role of dopamine in subjective valuation. We characterised the effects of dopaminergic modulation, using both an agonist and an antagonist, demonstrating its role in the coding of value in the IPS. Compared to sulpiride, bromocriptine enhanced the neural representation of value in the IPS. Moreover, a significant drug-by-valueby-trial phase interaction indicated that the dopaminergic modulation of neural response was specific to the late phase of the trials, when an action was needed to record the value.

425

While there is a rich literature on the role of dopamine in value learning (Bayer and Glimcher, 426 2005; Schultz, 1998; Schultz et al., 1997; Steinberg et al., 2013; Wise, 2004), there is relatively 427 little exploring its role in value computation during decision-making. Recent studies in healthy 428 429 adults and patients with Parkinson's disease have partly addressed this using a probabilistic 430 learning/choice task, demonstrating that dopamine biases choice towards more valuable 431 options (Jocham et al., 2011; Shiner et al., 2012; Smittenaar et al., 2012) and enhances the expression of value in the vmPFC (Jocham et al., 2011). However, the learning nature of these 432 tasks prevents a clear dissociation of dopaminergic effects on learning and performance/choice 433 (particularly given that in Jocham et al. (2011) the dopamine-modulated prediction error 434 expressed during the learning phase also predicted choice in the performance phase). Our 435 results concur with these findings, and complement them by demonstrating a dopaminergic 436 component of value computation in response to already well-learned items. Furthermore, the 437 realistic nature of the task and the inclusion of highly-familiar foods as auction items more 438 439 closely mimics every day value computations we make, which, compared to choosing between 440 probabilistic stimulus-reward associations, are more complex and are thought to entail integration of various attributes into a single measure of subjective value, which can be then 441 used as input for making choices (Rangel et al., 2008). 442

444 Interestingly, while our first analysis ("Model 1") replicated previous work in showing value signals in several brain regions including vmPFC (Bartra et al., 2013; Clithero and Rangel, 2013; 445 446 Hunt et al., 2012; O'Doherty, 2011), only in the IPS was value representation modulated by dopamine. The finding of a dopaminergic effect in the IPS and not in the vmPFC, and the 447 relatively late timing of this signal, suggests that a different, dopamine-sensitive value 448 computation is being processed in the IPS. We are cautious about interpreting a null effect in 449 vmPFC but it is worth noting that the association of BOLD activity in this region with value has 450 451 been generally established at the initial stages of the decision-making process and is thought to 452 serve as an input to later stages of decision-making (Rangel, 2010; Rangel and Clithero, 2013). 453 Conversely, posterior parietal cortex has been implicated as central to action-based decisionmaking (Dorris and Glimcher, 2004; Musallam et al., 2004; Platt and Glimcher, 1999; Sugrue et 454 455 al., 2004). Notably, one part of this region, the lateral intraparietal area has been found to represent a spatial map for guiding saccades (Snyder et al., 1997), and to encode the value of 456 rewards associated with individual saccades (Dorris and Glimcher, 2004; Platt and Glimcher, 457 1999; Sugrue et al., 2004). The parietal reach region analogously represents the movement of 458 459 forelimbs (Baumann et al., 2009; Connolly et al., 2003; Scherberger and Andersen, 2007), and 460 the firing of these neurons correlates with the expected value of the movement's outcome 461 (Musallam et al., 2004). These findings suggest that these two areas encode the value of movements. Human studies have also related measures of action value to activity in the 462 IPS/posterior parietal cortex (Chowdhury et al., 2013; Gershman et al., 2009; Hunt et al., 2012; 463 464 Iyer et al., 2010; Wunderlich et al., 2009).

One possibility is that dopaminergic enhancement of the neural representation of value reflects an increase in the signal to noise ratio (SNR) of the value representation. Evidence for this comes from studies of the decline in dopamine function with aging (reviewed in Bäckman et al., (2006)). Neural network simulations modelling age-related decline in dopaminergic function as attenuated gain control of SNR (Eppinger et al., 2011; Li et al., 2001) have suggested a plausible mechanistic link between reduced dopaminergic function, attenuated neural representation of

471 the value of stimuli and impairments in decision-making. Furthermore, studies in older adults demonstrated that the increased BOLD signal temporal variability (Samanez-Larkin et al., 472 2010a) and reduced neural representation of expected value (Samanez-Larkin et al., 2010b) 473 were predictive of poorer decision-making. Our results complement these findings by directly 474 475 showing the effects of dopaminergic modulation on the neural representation of value. 476 Moreover, the fact that the drug modulations occurred late in the trials (i.e. close to the final selection of the bid) suggests that dopamine modulates the dynamic process of fine tuning the 477 478 neural representation of value as the basis for completing the decision/action.

479 Behaviourally, we did not detect an effect of dopaminergic treatment on the magnitude of bids, 480 perhaps as consequence of the relatively mild pharmacological perturbation induced. However, the presence of significant neural alterations in the context of matched behaviour offers some 481 482 advantages to interpreting the former more clearly, in keeping with previous theoretical perspectives (Wilkinson and Halligan, 2004). Moreover, to the best of our knowledge, there is 483 no data demonstrating that dopamine increases value in a context dissociated from learning, A 484 485 more detailed analysis of the RTs revealed that the average time to decide on the size of the bid 486 was reduced in the sulpiride condition, suggestive of decreased deliberation on the value of 487 individual foods. Interestingly, this effect was paralleled by a trend towards larger bids in the sulpiride condition. In fact, the average bid under sulpiride is much closer to the mean bid in the 488 forced condition (see Figure 2A). Given that the bids in the forced condition were taken from a 489 490 random, uniform distribution, we speculate that sulpiride, and the proposed decrease in SNR of value representation, were associated with more random, less deliberative bids. 491

492

Finally, it is noteworthy that part of the posterior parietal region lying in close proximity to the dopamine-dependent value coding region identified in this study has been found to be related to goal-directed behaviour (Glascher et al., 2010). Given that dopamine has been implicated in mediating the balance between the habitual and goal-directed systems, with increased dopaminergic activity shifting the behaviour towards a more dominant goal-directed control

(de Wit et al., 2011, 2012; Wunderlich et al., 2012), and given the importance of valuation in goal-directed behaviour, we speculate that our agonist and antagonist drugs shifted this balance in different directions with the former promoting more measured, goal-directed responding and the latter, through reducing value SNR, prompting more rapid responses divorced from goal values. Of course, this is a speculation and our experimental design does not allow us to test it directly.

Certain limitations must be acknowledged. The between-subject design prevented analyses of 504 potential brain-behaviour correlations. Further, while pharmacological fMRI is widely used and 505 provides a targeted, non-invasive way of investigating neural processes, there are some basic 506 limitations of the approach. Given the limited data on dose and receptor occupancy 507 relationships for these agents, doses and administration protocols are based on the known 508 509 pharmacokinetics of these drugs and on previous studies that have successfully used them to perturb dopaminergic function (Cools et al., 2009; Dodds et al., 2009; Mehta et al., 2008; 510 Morcom et al., 2010). Dosages are also limited by what can be deemed clinically tolerable for 511 512 healthy volunteers. Furthermore, there are studies reporting effects different from our findings 513 - namely, enhanced neural value representation and improvement in performance associated with D2 antagonists, presumably linked to pre-synaptic auto-receptors effects (Jocham et al., 514 2011; Frank and O'Reilly, 2006). The preponderance of post-versus pre-synaptic effects is 515 believed to vary depending on the exact drug used, its concentration, the basal level of 516 dopamine in the system (discussed in Frank and O'Reilly (2006)), as well as on the brain area of 517 the studied effect, given the different distribution of post- and pre-synaptic receptors 518 throughout the brain (Kilts et al., 1987). It is not possible to entirely exclude the possibility of 519 520 auto-receptors effects in our study though the directionally of our effects does instil some 521 confidence that we are seeing predominantly post-synaptic effects.

In summary, we explored the role of dopamine in the neural representation of value without theconfound of learning. We investigated the direct role of dopamine in the expression of value that

has been already learned through life experience, and whose accurate expression is a requisite of goal-directed behaviour. Our results suggest that dopamine enhances the neural representation of value in the IPS. The effect predominates towards the end of the valuation process, at the point where the decision becomes explicit in action. These findings provide a dopamine-dependent mechanism underlying impaired decision-making in healthy individuals and clinical populations with reduced dopamine levels.

531 <u>References</u>

- 532 Bäckman, L., Nyberg, L., Lindenberger, U., Li, S.-C., and Farde, L. (2006). The correlative triad
- among aging, dopamine, and cognition: Current status and future prospects. Neurosci. Biobehav.
 Rev. *30*, 791–807.
- 535 Bartra, O., McGuire, J.T., and Kable, J.W. (2013). The valuation system: A coordinate-based meta-
- analysis of BOLD fMRI experiments examining neural correlates of subjective value.
 NeuroImage *76*, 412–427.
- 538 Baumann, M.A., Fluet, M.-C., and Scherberger, H. (2009). Context-Specific Grasp Movement
- 539 Representation in the Macaque Anterior Intraparietal Area. J. Neurosci. *29*, 6436–6448.
- Bayer, H.M., and Glimcher, P.W. (2005). Midbrain dopamine neurons encode a quantitative
 reward prediction error signal. Neuron *47*, 129–141.
- Becker, G.M., DeGroot, M.H., and Marschak, J. (1964). Measuring utility by a single-response
 sequential method. Behav. Sci. 9, 226–232.
- Berridge, K.C., and Robinson, T.E. (1998). What is the role of dopamine in reward: hedonic
 impact, reward learning, or incentive salience? Brain Res. Rev. 28, 309–369.
- 546 Caley, C.F., and Weber, S.S. (1995). Sulpiride: an antipsychotic with selective dopaminergic
 547 antagonist properties. Ann. Pharmacother. *29*, 152–160.
- 548 Chib, V.S., Rangel, A., Shimojo, S., and O'Doherty, J.P. (2009). Evidence for a Common
- 549 Representation of Decision Values for Dissimilar Goods in Human Ventromedial Prefrontal
 550 Cortex. J. Neurosci. 29, 12315 –12320.
- Chowdhury, R., Guitart-Masip, M., Lambert, C., Dayan, P., Huys, Q., Düzel, E., and Dolan, R.J.
 (2013). Dopamine restores reward prediction errors in old age. Nat. Neurosci. *16*, 648–653.
- 553 Clithero, J.A., and Rangel, A. (2013). Informatic parcellation of the network involved in the554 computation of subjective value. Soc. Cogn. Affect. Neurosci. nst106.
- Connolly, J.D., Andersen, R.A., and Goodale, M.A. (2003). FMRI evidence for a "parietal reach
 region" in the human brain. Exp. Brain Res. *153*, 140–145.
- Cools, R., Frank, M.J., Gibbs, S.E., Miyakawa, A., Jagust, W., and D'Esposito, M. (2009). Striatal
 Dopamine Predicts Outcome-Specific Reversal Learning and Its Sensitivity to Dopaminergic
 Drug Administration. J. Neurosci. 29, 1538–1543.
- Dodds, C.M., Clark, L., Dove, A., Regenthal, R., Baumann, F., Bullmore, E., Robbins, T.W., and
 Müller, U. (2009). The dopamine D2 receptor antagonist sulpiride modulates striatal BOLD
 signal during the manipulation of information in working memory. Psychopharmacology (Berl.)
 207, 35–45.
- Dorris, M.C., and Glimcher, P.W. (2004). Activity in Posterior Parietal Cortex Is Correlated with
 the Relative Subjective Desirability of Action. Neuron 44, 365–378.
- 566 Eppinger, B., Hämmerer, D., and Li, S.-C. (2011). Neuromodulation of reward-based learning and
 567 decision making in human aging. Ann. N. Y. Acad. Sci. *1235*, 1–17.
- Fiorillo, C.D., Tobler, P.N., and Schultz, W. (2003). Discrete coding of reward probability and
 uncertainty by dopamine neurons. Science *299*, 1898–1902.

- 570 Frank, M.J., and O'Reilly, R.C. (2006). A mechanistic account of striatal dopamine function in
- human cognition: psychopharmacological studies with cabergoline and haloperidol. Behav.
 Neurosci. *120*, 497–517.
- 573 Frank, M.J., Seeberger, L.C., and O'reilly, R.C. (2004). By carrot or by stick: cognitive 574 reinforcement learning in parkinsonism. Science *306*, 1940–1943.
- Gershman, S.J., Pesaran, B., and Daw, N.D. (2009). Human Reinforcement Learning Subdivides
 Structured Action Spaces by Learning Effector-Specific Values. J. Neurosci. 29, 13524–13531.
- Glascher, J., Daw, N., Dayan, P., and O'Doherty, J.P. (2010). States versus Rewards: Dissociable
 neural prediction error signals underlying model-based and model-free reinforcement learning.
- 579 Neuron *66*, 585–595.
- Grether, D.M., Plott, C.R., Rowe, D.B., Sereno, M., and Allman, J.M. (2007). Mental processes and
 strategic equilibration: An fMRI study of selling strategies in second price auctions. Exp. Econ. *10*, 105–122.
- Hothorn, T., Bretz, F., and Westfall, P. (2008). Simultaneous inference in general parametric
 models. Biom. J. Biom. Z. *50*, 346–363.
- Hunt, L.T., Kolling, N., Soltani, A., Woolrich, M.W., Rushworth, M.F.S., and Behrens, T.E.J. (2012).
 Mechanisms underlying cortical activity during value-guided choice. Nat. Neurosci. *15*, 470–476,
 S1–3.
- Iyer, A., Lindner, A., Kagan, I., and Andersen, R.A. (2010). Motor Preparatory Activity in Posterior
 Parietal Cortex is Modulated by Subjective Absolute Value. PLoS Biol. 8.
- Jocham, G., Klein, T.A., and Ullsperger, M. (2011). Dopamine-Mediated Reinforcement Learning
 Signals in the Striatum and Ventromedial Prefrontal Cortex Underlie Value-Based Choices. J.
 Neurosci. *31*, 1606–1613.
- 593 Kilts, C.D., Anderson, C.M., Ely, T.D., and Nishita, J.K. (1987). Absence of synthesis-modulating 594 nerve terminal autoreceptors on mesoamygdaloid and other mesolimbic dopamine neuronal
- populations. J. Neurosci. Off. J. Soc. Neurosci. 7, 3961–3975.
- Kvernmo, T., Härtter, S., and Burger, E. (2006). A review of the receptor-binding and
 pharmacokinetic properties of dopamine agonists. Clin. Ther. *28*, 1065–1078.
- Li, S.C., Lindenberger, U., and Sikström, S. (2001). Aging cognition: from neuromodulation torepresentation. Trends Cogn. Sci. *5*, 479–486.
- McClure, S.M., Daw, N.D., and Montague, P.R. (2003). A computational substrate for incentive
 salience. Trends Neurosci. *26*, 423–428.
- Mehta, M.A., Montgomery, A.J., Kitamura, Y., and Grasby, P.M. (2008). Dopamine D2 receptor
 occupancy levels of acute sulpiride challenges that produce working memory and learning
 impairments in healthy volunteers. Psychopharmacology (Berl.) *196*, 157–165.
- 605 Morcom, A.M., Bullmore, E.T., Huppert, F.A., Lennox, B., Praseedom, A., Linnington, H., and
- Fletcher, P.C. (2010). Memory encoding and dopamine in the aging brain: a
- 607 psychopharmacological neuroimaging study. Cereb. Cortex N. Y. N 1991 *20*, 743–757.
- Musallam, S., Corneil, B.D., Greger, B., Scherberger, H., and Andersen, R.A. (2004). Cognitive
 Control Signals for Neural Prosthetics. Science *305*, 258–262.

- 610 Niv, Y., Daw, N.D., Joel, D., and Dayan, P. (2007). Tonic dopamine: opportunity costs and the 611 control of response vigor. Psychopharmacology (Berl.) *191*, 507–520.
- O'Doherty, J.P. (2011). Contributions of the ventromedial prefrontal cortex to goal-directed
 action selection. Ann. N. Y. Acad. Sci. *1239*, 118–129.
- Pessiglione, M., Seymour, B., Flandin, G., Dolan, R.J., and Frith, C.D. (2006). Dopamine-dependent
 prediction errors underpin reward-seeking behaviour in humans. Nature 442, 1042–1045.
- 616 Pinheiro, J., Bates, D., and Sarkar, D. (2013). nlme: Linear and Nonlinear Mixed Effects
- 617 Modelsnlme: Linear and Nonlinear Mixed Effects Models.
- Plassmann, H., O'Doherty, J., and Rangel, A. (2007). Orbitofrontal Cortex Encodes Willingness to
 Pay in Everyday Economic Transactions. J. Neurosci. 27, 9984–9988.
- Platt, M.L., and Glimcher, P.W. (1999). Neural correlates of decision variables in parietal cortex.
 Nature *400*, 233–238.
- Rangel, A., Camerer, C., and Montague, P.R. (2008). A framework for studying the neurobiology
 of value-based decision making. Nat. Rev. Neurosci. *9*, 545–556.
- Robbins, T.W., and Everitt, B.J. (2007). A role for mesencephalic dopamine in activation:
 commentary on Berridge (2006). Psychopharmacology (Berl.) *191*, 433–437.
- Roesch, M.R., Calu, D.J., and Schoenbaum, G. (2007). Dopamine neurons encode the better option
 in rats deciding between differently delayed or sized rewards. Nat. Neurosci. *10*, 1615–1624.
- Samanez-Larkin, G.R., Kuhnen, C.M., Yoo, D.J., and Knutson, B. (2010a). Variability in nucleus
 accumbens activity mediates age-related suboptimal financial risk taking. J. Neurosci. Off. J. Soc.
 Neurosci. *30*, 1426.
- 631 Samanez-Larkin, G.R., Wagner, A.D., and Knutson, B. (2010b). Expected value information
 632 improves financial risk taking across the adult life span. Soc. Cogn. Affect. Neurosci. nsq043.
- 633 Scherberger, H., and Andersen, R.A. (2007). Target selection signals for arm reaching in the
 634 posterior parietal cortex. J. Neurosci. Off. J. Soc. Neurosci. 27, 2001–2012.
- 635 Schultz, W. (1998). Predictive reward signal of dopamine neurons. J. Neurophysiol. *80*, 1–27.
- Schultz, W., Dayan, P., and Montague, P.R. (1997). A Neural Substrate of Prediction and Reward.
 Science *275*, 1593–1599.
- Shiner, T., Seymour, B., Wunderlich, K., Hill, C., Bhatia, K.P., Dayan, P., and Dolan, R.J. (2012).
 Dopamine and performance in a reinforcement learning task: evidence from Parkinson's
- 640 disease. Brain *135*, 1871–1883.
- 641 Smittenaar, P., Chase, H.W., Aarts, E., Nusselein, B., Bloem, B.R., and Cools, R. (2012).
- Decomposing effects of dopaminergic medication in Parkinson's disease on probabilistic action
 selection learning or performance? Eur. J. Neurosci. *35*, 1144–1151.
- Snyder, L.H., Batista, A.P., and Andersen, R.A. (1997). Coding of intention in the posterior
 parietal cortex. Nature *386*, 167–170.
- Steinberg, E.E., Keiflin, R., Boivin, J.R., Witten, I.B., Deisseroth, K., and Janak, P.H. (2013). A causal
 link between prediction errors, dopamine neurons and learning. Nat. Neurosci. *16*, 966–973.

- 648 Sugrue, L.P., Corrado, G.S., and Newsome, W.T. (2004). Matching Behavior and the 649 Representation of Value in the Parietal Cortex. Science *304*, 1782–1787.
- Tobler, P.N., Fiorillo, C.D., and Schultz, W. (2005). Adaptive Coding of Reward Value by
 Dopamine Neurons. Science *307*, 1642–1645.
- Wiesel, F.A., Alfredsson, G., Ehrnebo, M., and Sedvall, G. (1980). The pharmacokinetics of
 intravenous and oral sulpiride in healthy human subjects. Eur. J. Clin. Pharmacol. *17*, 385–391.
- Wilkinson, D., and Halligan, P. (2004). The relevance of behavioural measures for functionalimaging studies of cognition. Nat. Rev. Neurosci. *5*, 67–73.
- Wise, R.A. (2004). Dopamine, learning and motivation. Nat Rev Neurosci *5*, 483–494.
- De Wit, S., Barker, R.A., Dickinson, A.D., and Cools, R. (2011). Habitual versus goal-directed
 action control in Parkinson disease. J. Cogn. Neurosci. 23, 1218–1229.
- De Wit, S., Standing, H.R., Devito, E.E., Robinson, O.J., Ridderinkhof, K.R., Robbins, T.W., and
- 660 Sahakian, B.J. (2012). Reliance on habits at the expense of goal-directed control following
- dopamine precursor depletion. Psychopharmacology (Berl.) *219*, 621–631.
- 662 Wunderlich, K., Rangel, A., and O'Doherty, J.P. (2009). Neural computations underlying action-663 based decision making in the human brain. Proc. Natl. Acad. Sci. U. S. A. *106*, 17199–17204.
- Wunderlich, K., Smittenaar, P., and Dolan, R.J. (2012). Dopamine enhances model-based over
 model-free choice behavior. Neuron *75*, 418–424.
- 666 (2012a). Bromocriptine SPC.
- 667 (2012b). Domperidone SPC.
- 668

670 Figure legends

Figure 1. Task structure and model specification. 671

A. The auction task featured 50 snack items presented as part of free and forced trials. Free and 672

673 forced trials, of duration 8s, were presented in a randomised order. After the bidding trial was

over, a 1s feedback screen showing the final bid was presented. This was followed by a 0.5s 674

blank screen. On 30 random occasions during the course of the task, a 6s null trial with a 675

fixation cross was presented after the blank screen. 676

B. fMRI model 1 schematic. Each bidding trial was modelled as a boxcar function (depicted as a 677

pink rectangle), from the onset of the food stimulus until the bid was confirmed (duration equal 678 to RT).

679

C. fMRI model 2 schematic. Two time points within each bidding trial were modelled as events 680

within the trial (0s stick or delta functions, depicted as pink rectangles): an early phase 681

regressor set at the time of food stimulus onset, and a late phase regressor set at a time half-way 682

from the food photo onset to the bid confirmation (RT/2), separately for each trial. 683

Figure 2. Behavioural results. 684

A. Average bid by treatment group in the free trial condition. Error bars represent SEM of each 685 subject's average bid. Presented on the same graph is the mean of the uniform distribution of 686 instructed forced bids. 687

B. Average RT by treatment group and trial type. Error bars represent SEM of each subject's 688 average RT. 689

690

- 692 **Figure 3. Neural representation of value**.
- 693 Significant areas of activation were rendered onto a standard SPM8 T1 template image, with
- 694 corronal and sagittal sections presented at the coordinates appropriate for displaying relevant
- 695 regions.
- A. The neural representation of value was found within the pre-defined 10mm-radius sphere in
- 697 the vmPFC region (p_{FWE} <0.05, small-volume corrected).
- B. Equally, value-coding clusters were found in regions surviving the whole-brain correction at
- the cluster-level (p_{FWE} <0.05). These include a large cluster encompassing the left and right
- 700 posterior parietal cortex (maxima located in the region of IPS on both sides) and extending to
- the left fusiform gyrus and further clusters in middle and inferior frontal gyri bilaterally and in
- the right fusiform / lingual gyrus.
- Full details of the activation foci are given in Table 1.

Figure 4. Dopaminergic modulation of the neural representation of value.

Significant areas of activation were rendered onto the standard SPM8 T1 template image, with
 corronal and sagittal sections presented at the coordinates appropriate for displaying relevant
 regions.

A. Activation areas in the left and right IPG/IPS and in the right middle frontal gyrus that

exhibited an effect of drug on the neural representation of value (p<0.001 uncorrected, k>20

710 voxels).

- B. Displayed in green are the activation areas in the left and right IPG/IPS in which there was an
- enhancement of the neural representation of value in the bromocriptine compared to the
- sulpiride treatment group (p_{FWE}<0.05, whole-brain corrected at the cluster-level). Value-coding

clusters, common to all three treatment groups, are presented in magenta ((p_{FWE}<0.05, whole-

715 brain corrected at the cluster-level).

716 C. Presented inside the magenta box are the parameter estimates of the neural representation of

value averaged per treatment groups, extracted from the large value-coding cluster spanning

the left and right posterior parietal cortex (presented in magenta on the images in panel B).

D. Presented inside the green box are the parameter estimates of the neural representation of

value averaged per treatment groups, extracted from the left and right IPG/IPS clusters of the

721 bromocriptine versus sulpiride contrast (presented in green on the images in panel B).

Firror bars represent SEM. Full details of the activation foci are given in Tables 2 and 3.

723 Figure 5. Dopaminergic treatment modulates the neural representation of value in the

724 left inferior parietal gyrus/intraparietal sulcus during the late stage of valuation.

725 Corronal (at y=-54mm to the anterior commissure) and sagittal sections (at x=-54mm to the left

of the mid-line) from the standard SPM8 T1 template image.

A. The analysis was confined to a 10mm-radius sphere around the voxel in the left IPG/IPS that
showed the strongest dopamine-dependent modulation in model 1, and is depicted here in
green. Presented in yellow are the voxels within this sphere showing a significant treatment
(placebo, bromocriptine, sulpiride) by time (early, late) interaction. For display purposes, both
contrasts are presented at p<0.01 uncorrected.

B. Presented inside the yellow box are the parameter estimates of the neural representation of
value for each of the six conditions: treatment (placebo/bromocriptine/sulpiride) and time
(early/late). The parameter estimates were extracted from the voxels exhibiting the treatmentby-time interaction within the described sphere (presented in yellow on the image in panel A).

Fror bars represent SEM. Full details of the activation foci are given in Table 4.

737 <u>Table legends</u>

- **Table 1.** Regions correlated with subjective value.
- **Table 2.** Regions exhibiting a dopaminergic modulation of the neural representation of value.
- 740 **Table 3.** Regions with an enhanced neural representation of value under bromocriptine,
- 741 compared to sulpiride.
- 742 **Table 4.** Activation peak exhibiting a time-by-treatment interaction in the left IPG/IPS.

<u>Figures</u>

Figure 1

Α Free £1.80 ╋ Forced £0.40 Please bid £0.40 Bidding trial Feedback ŀ Blank Null (30x random) 8s 1s 0.5s 6s С В 1st Final 1st Final response response response response + + ╉ +┥ ł t 0s 0s RT/2 RT 8s RT/2 RT 8s






Figure 3




Figure 4





Figure 5



<u>Tables</u>

Table 1 Regions correlated with subjective value.

	Side	Cluster	Peak MN coordinates		Peak scores		
		Size					
Region			x	У	Z	т	Z
Intraparietal Sulcus	L/R	7354	-26	-66	46	6.4	5.32
Middle Frontal Gyrus	L	425	-24	2	58	5.75	4.91
Middle Frontal Gyrus	R	744	25	-1	54	5.5	4.74
Fusiform Gyrus/Lingual Gyrus	R	833	28	-64	-8	5.24	4.57
Inferior Frontal Gyrus	R	604	50	6	26	4.86	4.3
Middle Frontal Gyrus	R	286	46	42	10	4.25	3.86
Inferior Frontal Gyrus	L	248	-48	2	34	4.1	3.74
Anterior Cingulate/Medial Frontal Gyrus*	L/R	81	0	44	2	3.71	3.43

p<0.05 whole-brain FWE correction for multiple comparisons at the cluster-level (p<0.001 uncorrected threshold).

*Survives p<0.05 small-volume FWE correction within a 10mm sphere around the vmPFC coordinates (-3, 42, -6) from the work of Chib et al. (2009).

	Side	Cluster Size	Peak MNI coordinates			Peak scores	
Region			x	Y	z	F	z
Middle Frontal Gyrus	R	55	32	0	58	12.62	3.86
Inferior Parietal Gyrus/Intraparietal Sulcus	L	63	-50	-50	46	11.17	3.63
Inferior Parietal Gyrus/Intraparietal Sulcus	R	40	52	-50	48	9.95	3.42

Table 2 Regions exhibiting a dopaminergic modulation of the neural representation of value.

p<0.001 uncorrected, extent k>20 voxels.

Table 3 Regions with an enhanced neural representation of value under bromocriptine, compared to sulpiride.

	Side	Cluster Size	Peak MNI coordinates			Peak scores	
Region			x	У	z	т	Z
Inferior Parietal Gyrus/Intraparietal Sulcus	L	494	-50	-50	46	4.66	4.14
Inferior Parietal Gyrus/Intraparietal Sulcus	R	363	52	-50	48	4.45	3.99

p<0.05 whole-brain FWE correction for multiple comparisons at the cluster-level (p<0.001 uncorrected threshold).

	Side	Cluster Size	Peak MNI coordinates			Peak scores		
Region			x	Y	Z	F	Z	
Inferior Parietal	L	10	-54	-54	50	8.79	3.39	
Gyrus/Intraparietal Sulcus								

Table 4 Activation peak exhibiting a time-by-treatment interaction in the left IPG/IPS.

p<0.05 small-volume FWE correction within a 10mm sphere around the peak voxel in the left IPG/IPS (-50,-50, 46) which showed an effect of drug across the entire bidding trial (model 1).